Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.
You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!
If you have any problems with the registration process or your account login, please contact contact us.
Wound Management Technologies, Inc., (WNDM: OTCQB) a leader in advanced wound care solutions, is meeting the challenge of a rise in type 2 diabetes in the US, as chronicled by a new report by the Center for Disease Control (CDC). The report published in the October 22, 2010 journal Population Health Metrics recommends that proper diet and physical activity can prevent type 2 diabetes and reduce its complications, among the most severe of which are diabetic ulcers and amputations. Wound Management, exclusive worldwide licensee and distributor of CellerateRX® wound care powder and gel, further recommends that existing diabetic patients who suffer from moderate to heavily exudative wounds should ask their doctor whether CellerateRX® may be an effective treatment for them. CellerateRX® is the only activated Type 1 collagen-based product reimbursed by Medicare and has been shown to effectively manage diabetic ulcers.
CellerateRX® Effectively Manages Diabetic Ulcers
Wound Care Innovations’ advanced wound care collagen product, CellerateRX®, has been shown in multiple clinical applications and settings to be extremely effective in managing these challenging diabetic wounds. In one study, wounds where CellerateRX® was applied were healed within five (5) weeks with a once or twice per week application. This is in contrast to the control wounds that were only approximately 80% healed at twelve (12) weeks. “The ideal product to effectively manage these difficult wounds provides for quality outcomes in a cost effective manner,” said Dr. Larry Baratta, VP of Medical Affairs. “CellerateRX® has been shown to do just this.” Jane Fore MD, FAPWCA, FACCWS, Medical Director, Tri-State Wound Care and Hyperbaric Center states, “CellerateRX® is the standard of care in my clinic. This product is compatible with other wound care products and gives the wound environment the basic building blocks for growth, and contributes an essential part of the wound matrix that supports the migration of cells to healing tissues. Wound healing deficiencies are more common in diabetics and CellerateRX® collagen provides an essential factor that aids in overcoming challenges in healing diabetic wounds.”
CellerateRX® Activated Collagen is the Differentiator
CellerateRX®’s activated collagen (approximately 1/100th the size of native collagen) delivers the essential benefits of collagen to a wound immediately, where other forms of native, intact collagen in commercially available products require time for the body to prepare the collagen for use in the wound healing process. In people with compromised health or circulation, the difference in wound healing can be significant.
CellerateRX® is FDA cleared for all wound types except for 3rd degree burns and is available in both powder and gel form. In addition to being used in healthcare settings throughout the country, CellerateRX® is easily applied by patients by themselves at home. CellerateRX® is safe, non-toxic, and easy to use; in fact, the product can be purchased through Wound Care Innovations, LLC website at http://www.celleraterx.com/pages/products.php